A Study of Apabetalone in Subjects With Long -COVID

Summary

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

Timeline

Start

2025-04-15

Primary completion

2025-12-30

Completion

2026-03-30

Drugs

Indications